6:11 PM
Aug 01, 2007
 |  BC Extra  |  Company News

Anadys returns ANA380 rights, restructures

ANDS announced plans to restructure and discontinue development of ANA380, a nucleotide analog viral polymerase inhibitor in Phase II testing to treat HBV. The announcement follows last Friday's news that ANDS and partner Novartis (NVS; SWX:NOVN) were dropping ANA975, a prodrug of isatoribine, a toll-like receptor 7 (TLR7) agonist, to treat HCV (

Read the full 263 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >